Larynx cancer
MONDO:0002352A primary or metastatic malignant neoplasm involving the larynx. The majority are carcinomas.
Also known as: cancer of larynx, larynx cancer, malignant laryngeal neoplasm, malignant laryngeal tumor, malignant laryngeal tumour, malignant larynx neoplasm, malignant larynx tumor, malignant larynx tumour
2866 clinical trials for this condition and its sub-types, 41 tagged with Larynx cancer itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Larynx cancer
-
Laryngeal carcinoma 56 trials · 114 incl. sub-types
8 sub-types
- Laryngeal squamous cell carcinoma 72 trials · 77 incl. sub-types Sub-types →
- Glottis carcinoma 6 trials · 10 incl. sub-types Sub-types →
- Carcinoma of supraglottis 1 trial · 2 incl. sub-types Sub-types →
- Larynx carcinoma in situ 1 trial Sub-types →
- Subglottis carcinoma 1 trial Sub-types →
- Laryngeal adenoid cystic carcinoma 0 trials
- Laryngeal mucoepidermoid carcinoma 0 trials
- Laryngeal small cell carcinoma 0 trials
-
Glottis cancer 0 trials · 10 incl. sub-types
1 sub-type
- Glottis carcinoma 6 trials · 10 incl. sub-types Sub-types →
-
Supraglottis cancer 1 trial · 3 incl. sub-types
1 sub-type
- Carcinoma of supraglottis 1 trial · 2 incl. sub-types Sub-types →
-
Subglottis cancer 0 trials · 1 incl. sub-types
1 sub-type
- Subglottis carcinoma 1 trial Sub-types →
-
Aryepiglottic fold cancer 0 trials
-
Laryngeal cartilage cancer 0 trials
-
Laryngeal sarcoma 0 trials
2 sub-types
- Laryngeal leiomyosarcoma 0 trials
- Larynx liposarcoma 0 trials
Most studied deeper sub-types
-
Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?
Disease control OngoingThis phase I trial is testing whether a combination of three treatments — an experimental drug called elimusertib, precise radiation therapy, and the immunotherapy pembrolizumab — can shrink or stabilize recurrent head and neck cancer that cannot be removed by surgery. The study …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New hope for head and neck cancer: Three-Drug showdown after immunotherapy fails
Disease control OngoingThis study tests three different drug combinations in 430 adults with advanced head and neck cancer that has spread or returned after prior immunotherapy. The goal is to see if adding bevacizumab to standard chemo, or using atezolizumab plus bevacizumab, works better than the usu…
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Immunotherapy-Chemo cocktail shows promise in head and neck cancer trial
Disease control OngoingThis phase II trial is testing whether combining the immunotherapy drug cemiplimab with low doses of two chemotherapy drugs (paclitaxel and carboplatin) can shrink tumors in people with head and neck cancer that has come back or spread. The study includes 46 participants who have…
Phase 2 • Sponsor: Marcelo Bonomi • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New Drug-Radiation combo shows promise for Tough-to-Treat head and neck cancer
Disease control OngoingThis early-phase trial is testing whether adding the drug peposertib to standard radiation therapy is safe and effective for people with advanced head and neck cancer who cannot take the chemotherapy drug cisplatin. The study involves 21 participants and aims to find the best dos…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail shows promise in larynx cancer without surgery
Disease control OngoingThis study tested a combination of two chemotherapy drugs (cisplatin and docetaxel) plus an immunotherapy drug (pembrolizumab) in 28 patients with stage II or III laryngeal cancer. The goal was to see if this drug-only approach could control the cancer and avoid the need for surg…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could a Chemo-Immunotherapy cocktail spare head and neck cancer patients from radiation?
Disease control OngoingThis phase 2 trial tests a combination of two chemotherapy drugs (carboplatin and nab-paclitaxel) plus an immunotherapy drug (durvalumab) given before surgery for people with locally advanced head and neck cancer. The goal is to shrink or eliminate the tumor so that radiation—whi…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
AI messages aim to curb drinking in cancer survivors
Knowledge-focused By invitation onlyThis study tests whether AI-generated messages can change how cancer survivors think about alcohol and cancer risk. About 850 adults who have had certain cancers and currently drink alcohol will view different messages. Researchers will measure changes in their beliefs about canc…
Sponsor: University of Miami • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC